Comparison of Pulmonary Function Decline in Steroid-Treated and Steroid-Naive Patients with Duchenne Muscular Dystrophy

被引:12
|
作者
Sawnani, Hemant [1 ,2 ]
Horn, Paul S. [2 ,3 ]
Wong, Brenda [2 ,3 ]
Darmahkasih, Andrew [4 ]
Rybalsky, Irina [2 ,3 ]
Shellenbarger, Karen C. [3 ]
Tian, Cuixia [2 ,3 ]
Rutter, Meilan M. [2 ,5 ]
Simakajornboon, Narong [1 ,2 ]
Amin, Raouf [1 ,2 ]
Gurbani, Neepa [1 ,2 ]
Pascoe, John [1 ,2 ]
Burrows, Carolyn [1 ]
Khirani, Sonia [6 ,7 ]
Amaddeo, Alessandro [6 ]
Fauroux, Brigitte [6 ]
机构
[1] Cincinnati Childrens Hosp Med Ctr, Div Pulm Med, MLC 7041,3333 Burnet Ave, Cincinnati, OH 45229 USA
[2] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA
[3] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA
[4] Wayne State Univ, Sch Med, Detroit, MI USA
[5] Cincinnati Childrens Hosp Med Ctr, Div Endocrinol, Cincinnati, OH 45229 USA
[6] Necker Univ Hosp, Pediat Noninvas Ventilat & Sleep Unit, Paris, France
[7] ASV Sante, Gennevilliers, France
来源
JOURNAL OF PEDIATRICS | 2019年 / 210卷
关键词
RESPIRATORY-FUNCTION; PREDNISONE THERAPY; HEIGHT; TRIAL; SURVIVAL; IMPACT;
D O I
10.1016/j.jpeds.2019.02.037
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective To describe and compare the lung function decline in patients with Duchenne muscular dystrophy on glucocorticoid therapy in contrast with glucocorticoid-naive patients, and to define the deciles of pulmonary decline in glucocorticoid-treated patients. Study design This retrospective study examined lung function of patients with Duchenne muscular dystrophy over 6 years of age followed between 2001 and 2015 at 2 centers-glucocorticoid-treated patients in Cincinnati, Ohio, and glucocorticoid-naive patients in Paris, France. Forced vital capacity (FVC, FVC%), forced expiratory volume in 1 second, maximal inspiratory pressure, maximal expiratory pressure, and peak expiratory flow data were analyzed. Only FVC data were available for the French cohort. Results There were 170 glucocorticoid-treated patients (92%), 5 patients (2.7%) with past glucocorticoid use, and 50 French glucocorticoid-naIve patients. The peak absolute FVC was higher and was achieved at earlier ages in glucocorticoid-treated compared with glucocorticoid-naive patients (peak FVC, 2.4 +/- 0.6 L vs 1.9 +/- 0.7 L; P < .0001; ages 13.5 +/- 3.0 years vs 14.3 +/- 2.8 years; P = .03). The peak FVC% was also higher and was achieved at earlier ages in glucocorticoid-treated patients (peak FVC%, 105.1 +/- 25.1% vs 56 +/- 20.9%; P < .0001; ages 11.9 +/- 2.9 years vs 13.6 +/- 3.2 years; P = .002). Rates of decline for both groups varied with age. Maximal rates of decline were 5.0 +/- 0.26% per year (12-20 years) for glucocorticoid-treated and 5.1 +/- 0.39% per year for gluco-corticoid-naive patients (11-20 years; P = .2). Deciles of FVC% decline in glucocorticoid-treated patients show that patients experience accelerated decline at variable ages. Conclusions These data describe nonlinear rates of decline of pulmonary function in patients with Duchenne muscular dystrophy, with improved function in glucocorticoid-treated patients. FVC% deciles may be a useful tool for clinical and research use.
引用
收藏
页码:194 / +
页数:9
相关论文
共 50 条
  • [41] Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests
    Miller, Natalie F.
    Alfano, Lindsay N.
    Iammarino, Megan A.
    Connolly, Anne M.
    Moore-Clingenpeel, Melissa
    Powers, Brenna R.
    Tsao, Chang-Yong
    Waldrop, Megan A.
    Flanigan, Kevin M.
    Mendell, Jerry R.
    Lowes, Linda P.
    PEDIATRIC NEUROLOGY, 2020, 113 : 15 - 20
  • [42] EPIDURAL LIPOMATOSIS IN STEROID-TREATED PATIENTS
    FESSLER, RG
    JOHNSON, DL
    BROWN, FD
    ERICKSON, RK
    REID, SA
    KRANZLER, L
    SPINE, 1992, 17 (02) : 183 - 188
  • [43] BOWEL PERFORATION IN STEROID-TREATED PATIENTS
    REMINE, SG
    MCILRATH, DC
    ANNALS OF SURGERY, 1980, 192 (04) : 581 - 586
  • [44] Diffuse peritonitis in steroid-treated patients
    Menegaux, F
    Chenard, X
    Wechsler, B
    Boutin, Z
    Chigot, JP
    DIGESTIVE SURGERY, 1998, 15 (03) : 247 - 251
  • [45] Low-dose steroid therapy for cardiomyopathy in Duchenne Muscular Dystrophy patients
    Ishigaki, K.
    Murakami, T.
    Saito, T.
    Sato, T.
    Kajino, S.
    Kato, I.
    Osawa, M.
    NEUROMUSCULAR DISORDERS, 2012, 22 (9-10) : 866 - 866
  • [46] e-NO peak versus e-NO plateau values in evaluating e-NO production in steroid-naive and in steroid-treated asthmatic children and in detecting response to inhaled steroid treatment
    Silvestri, M
    Spallarossa, D
    Battistini, E
    Fregonese, B
    Rossi, GA
    PEDIATRIC PULMONOLOGY, 2001, 31 (01) : 37 - 43
  • [47] Longitudinal assessment of respiratory function in Duchenne muscular dystrophy (DMD): The effect of steroid therapy
    LoMauro, Antonella
    Romei, Marianna
    Gandossini, Sandra
    D'Angelo, Maria Grazia
    Aliverti, Andrea
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [48] Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy
    Alman, BA
    Raza, SN
    Biggar, WD
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2004, 86A (03): : 519 - 524
  • [49] Lung Volume Recruitment Slows Pulmonary Function Decline in Duchenne Muscular Dystrophy
    McKim, Douglas A.
    Katz, Sherri L.
    Barrowman, Nicholas
    Ni, Andy
    LeBlanc, Carole
    ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2012, 93 (07): : 1117 - 1122
  • [50] PREDICTION OF THERAPEUTIC RESPONSE IN STEROID-TREATED PULMONARY SARCOIDOSIS
    SNIDER, GL
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1985, 132 (05): : 1139 - 1140